Tunisian consensus on the management of Helicobacter Pylori infection

##plugins.themes.academic_pro.article.sidebar##

Published Nov 6, 2023
Download
pdf
Vol. 101 No. 8-9 (2023): Tunis med aug-sept 2023

##plugins.themes.academic_pro.article.main##

Mouna Medhioub
Department of Gastroenterology - Mohamed Taher Maamouri Hospital, Nabeul - Tunisia
Lassaad Chtourou
Department of Gastroenterology - Hédi Chaker Hospital, Sfax- Tunisia
https://orcid.org/0000-0003-1654-5104
Mehdi Kchaou
Private gastrology practice, Avicenne clinic, Tunis -Tunisia
Amal Khsiba
Department of Gastroenterology, Mohamed Taher Maamouri Hospital, Nabeul -Tunisia
Mejda Zakhama
Department of Gastroenterology , Fattouma Bourguiba Hospital , Monastir -Tunisia
Wafa Ben Ameur
Department of Gastroenterology , Sahloul Hospital, Sousse, Tunisia.
Manel Moalla
Departement of Gastroenterology , Hedi chaker Hospital , Sfax - Tunisia
Haythem Yacoub
Department of Gastroenterology B, La Rabta Hospital, Tunis -Tunisia
Shema Ayadi
Departement of Gastroenterology, Charles Nicolle Hospital, Tunis -Tunisia
Bochra Bouchabou
Departement of Gastroenterology , Mongi Slim Hospital, Tunis -Tunisia.
Hajer Battikh
Department of Microbiology , La Rabta Hospital, Tunis -Tunisia
Meriem Zribi
Department of Microbiology , La Rabta Hospital, Tunis -Tunisia
Nadia Siala
Department of Pediatrics, Mongi Slim Hospital, Tunis -Tunisia.
Mohamed Moussadek Azouz
Departement of Gastroenterology, Mohamed Taher Maamouri Hospital, Nabeul -Tunisia.
Ali Amouri
Department of Gastroenterology, Hedi chaker Hospital , Sfax - Tunisia
Mohamed Nabil Abdelli
Department of Gastroenterology , Tunis Main Military Training Hospital, Tunis, Tunisia
Leila Safer
Department of Gastroenterology ,Fattouma Bourguiba Hospital, Monastir -Tunisia
Norsaf Bibani
Department of Gastroenterology, Habib THameur Hospital, Tunis -Tunisia
Nadia Ben Mustapha
Department of Gastroenterology A, La Rabta Hospital, Tunis -Tunisia
Aya Hammami
Department of Gastroenterology, Sahloul Hospital , Sousse-Tunisia
Mehdi Abdelwaheb
Department of Gastroenterology , Fattouma Bourguiba Hospital, Monastir -Tunisia
Rym Ennaifer
Departement of Gastroenterology , Mongi Slim Hospital, Tunis -Tunisia
Taieb Jomni
Department of Gastroenterology, Hospital of the Internal Security Forces ,La Marsa-Tunisia
Monia Fekhi
Department of Gastroenterology A, Hôpital la Rabta, Tunis -Tunisia

Abstract

Helicobacter pylori infection is the most common infectious disease worldwide. It is associated with duodenal and gastric ulcer disease and the risk of gastric neoplasia. The management of helicobacter pylori infection currently represents a real challenge for clinicians, given the ever-increasing rate of resistance of Helicobacter pyolori to various antibiotics. In this consensus document, we present recommendations adapted to the Tunisian context, including indications for the detection of helicobacter pylori infection, indications for the use of different diagnostic methods, and a therapeutic strategy for the management of Helicobacter pylori infection.

Keywords:

diagnosis , treatment , resistance , antibiotics, Tunisia, Africa

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 323:1311-5.
  2. World health organization. Schistosomes, Liver Flakes and Helicobacter pylori. Iarc monographs on the evaluation of carcinogenic risks to humans.1994; 61:1-241.
  3. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection : the Maastricht VI/Florence consensus report. Gut 2022 ; 71:1724- 62.
  4. Société tunisienne de gastro-entérologie. Actualisation du consensus du traitement de la maladie ulcéreuse gastroduodénale non compliquée de l’adulte en Tunisie [Internet]. [Cité 26 avr 2022]. http://www.santetunisie.rns.tn/images/articles/ULCEREUSE.pdf
  5. World Gastroenterology Organisation Global Guidelines. Helicobacter pylori dans les pays en voie de développement [Internet]. [Cité 26 avr 2022]. https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori- french-2010.pdf
  6. Djemel N, Khammasi S, Bouzaidi S. Prévalence de l’Hélicobacter pylori en Tunisie chez des témoins asymptomatiques et au cours de la dyspepsie non ulcéreuse et de l’ulcère duodénal. Etude prospective de 183 cas. Tunisie Med 1995 ; 73: 373-7.
  7. Ben Ammar A, Cheikh I, Ouerghi H, Chaabouni H, Kchaou M, Ben Mami N. Prévalence de l'infection à Helicobacter pylori dans la maladie ulcéreuse duodénale. Résultats d'une étude prospective à propos de 78 ulcéreux duodénaux AINS négatifs Tunisie Med 2002 ; 80: 599-604.
  8. Bouali.R, Ben Moussa.M, Jemaa.A, et al. High prevalence of helicobacter pylori infection in Tunisia. The American Journal of Gastroenterology 2003; 98 (Suppl. 1): S40.
  9. Jmaa.R, Aissaoui.B, Golli.L et al. Les particularités de la gastrite chronique à Helicobacter pylori au centre ouest de la Tunisie. Tunisie Medicale 2010 ;88 : 147-151 .
  10. Siai K, M. Ghozzi, H. Ezzine, N. Medjahed, M.M. Azzouz . Prevalence and risk factors of Helicobacter pylori infection in Tunisian children: 1055 children in Cap- Bon (northeastern Tunisia). Gastroenterol Clin Biol 2008;32:881-6
  11. Bai X, Xi C, Wu J. Survival of Helicobacter pylori in the wastewater treatment process and the receiving river in Michigan, USA. J Water Health 2016;14:692-98.
  12. Ranjbar R, Khamesipour F, Jonaidi-Jafari N, Rahimi E. Helicobacter pylori in bottled mineral water: genotyping and antimicrobial resistance properties. BMC Microbiol. 2016;16:1-10.
  13. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. janv 2017;66:6-30.
  14. De Korwin JD. Helicobacter pylori : quand rechercher une infection et la traiter chez l’adulte ? Rev Médecine Interne 2021;42:482-91.
  15. Andoulo FA, Noah Noah D, Tagni-Sartre M, Ndjitoyap EC, Ngu Blackett K. Epidémiologie de l’infection à Helicobacter Pylori à Yaoundé: de la particularité à l’énigme Africaine. Pan Afr Med J [Internet]. 2013 [cité 12 avr 2022];16. Disponible sur: http://www.panafrican-med-journal.com/content/article/16/115/full/
  16. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
  17. Lamarque D, Burucoa C, Courillon-Mallet A, et al. Révision des recommandations françaises sur la prise en charge de l’infection par Helicobacter pylori. Hépato Gastro 2012 ; 19 : 475-502.
  18. Jung HK, Kang SJ, Lee YC et al. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver 2021 ;15:168-95.
  19. Kato M, Ota H, Okuda M et al. Guidelines for themanagement of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter 2019; e12597.
  20. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368:2041-2.
  21. Kim BJ, Kim HS, Jang HJ, Kim JH. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract 2018; 9 :1-8.
  22. Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter 2020 ;25(Suppl. S1):e12741.
  23. Dore MP, Pes GM. What Is New in Helicobacter pylori diagnosis. An Overview. J Clin Med 2021;10:2091.
  24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996 ;20:1161-81.
  25. Shukla S, Pujani M, Agarwal A, Pujani M, Rohtagi A. Correlation of serology with morphological changes in gastric biopsy in Helicobacter pylori infection and evaluation of immunohistochemistry for H. pylori identification. Saudi J Gastroenterol 2012 18:369-74.
  26. Wang XI, Zhang S, Abreo F, Thomas J. The role of routine immunohistochemistry for Helicobacter pylori in gastric biopsy. Ann Diagn Pathol 2010 ;14:256-9.
  27. Cerqueira L, Fernandes RM, Ferreira RM et al. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013;51:1887-93.
  28. Heluwaert F. Helicobacter Pylori : diagnostic, indications et modalités d’éradication. Post’U 2022. [Internet]. [cité 23 avr 2022]. Disponible sur: https://www.fmcgastro.org/texte-postu/postu-2022/helicobacter-pylori-diagnostic-indications-et-modalites-deradication/).
  29. Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med 2015 ; 3:10.
  30. Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases 2021 ;9 :133-47.
  31. Burucoa C, Delchier JC, Courillon-Mallet A et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 2013; 18:169-79.
  32. Blecker U, Vandenplas Y. Helicobacter pylori serology. J Clin Microbiol 1993 ;31:173.
  33. Malfertheiner P, Mégraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-64.
  34. DeKorwin JD, Kalach N, Raymond J, Burucoa C. Prise en charge diagnostique et thérapeutique en cas d’infection à Helicobacter pylori. EMC-gastroentérologie 2014; 93:1-11.
  35. Logan, R.P.H. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998 ; 43:S47-S50.
  36. Leide-Svegborn S, Stenström, K, Olofsson, M et al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur. J. Nucl. Med. Mol. Imaging 1999; 26:573–80.
  37. Best LM, Takwoingi Y, Siddique S et al. Non-invasive diagnostictests for Helicobacter pylori infection. Cochrane Database Syst. Rev. 15 Mar 2018;3:CD012080.
  38. Ferwana M, Abdulmajeed I, Alhajiahmed A et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 2015 ;21:1305-14.
  39. Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002;136:280-7.
  40. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006 ;101:848-63.
  41. Liu WZ, Xie Y, Lu H et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.
  42. Choi YJ, Kim N, Lim J et al. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter 2012 ; 17:77-85.
  43. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. Aliment Pharmacol Ther 2004 ; 20:1001-17.
  44. Kato S, Shimizu T, Toyoda S et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood, 2018. J. Jpn. Soc. Pediatric Gastroenterol Hepatol Nutr 2018; 32:92-136.
  45. El-Serag H.B, Kao JY, Kanwal F et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol 2018; 16:992-1002.
  46. Opekun AR, Zierold C, Rode A et al. Clinical Performance of the Automated LIAISON® Meridian H. pylori SA Stool Antigen Test. Biomed Res Int 2020 ; 19 :7189519.
  47. Deguchi R, Matsushima M, Suzuki T et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J. Gastroenterol 2009; 44:713-6.
  48. Domínguez J, Forné M, Blanco S et al. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection before and after eradication therapy. Aliment Pharmacol Ther 2006 ; 23:1735-40.
  49. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. Helicobacter 2004; 9:347-68.
  50. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection by stool antigen determination: A systematic review. Am J Gastroenterol.2001; 96:2829–283.
  51. Attumi TA, Graham DY. Follow-Up testing after treatment of Helicobacter pylori infections: Cautions, caveats, and recommendations. Clin Gastroenterol Hepatol.2011 ; 9:373-5.
  52. Attumi TA, Graham DY. High-Dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014; 19:319-22.
  53. Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol2013;19:8188-91.
  54. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36:414-25.
  55. Ben Mansour k, Burucoa C, Zribi M, Masmoudi A, Karoui S, Kallel L et al. Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentrestudy . Ann Clin Microbiol Antimicrob 2010; 9 :2-7.
  56. Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021; 70:1815–22.
  57. Chtourou L, Moalla M, Mnif B et al. Prevalence of Helicobacter pylori resistance to clarithromycin in Tunisia. J Med Microbiol. 2022 Aug;71(8).
  58. Benejat L, Ducournau A, Domingues Martins C. et al. Epidémiologie de l’infection à Helicobacter pylori en France en 2020 : Données de surveillance du CNR Campylobacters et Helicobacters. Bull Epidémiol Hebd 2021;:275-82
  59. Tursi A, Di Mario F,Franceschi M ,De Bastiani R, EliseiW,Baldassarre G, et al. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. Helicobacter 2017 ; 22 : e12371
  60. Tursi A, Franceschi M, Allegretta L,Savarino E,De Bastiani R, Elisei W et al.Effectiveness and safety of Pylera® in patients infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis. 2018; 36:264-68.
  61. W A De Boer , R J Van Etten, B A Van De Wouw, P M Schneeberger, A H Van Oijen, J B Jansen. Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole. Aliment Pharmacol Ther 2000 ;14:85-9.
  62. Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Advances in experimental medicine and biology 2019; 1149:211-25.
  63. Yang-Jie Zhu , Yi Zhang , Ting-Yi Wang , Jing-Tao Zhao , Zhe Zhao , Jian-Ru Zhu et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol [internet]. 2020 [cité 26 avri 2023] ;13:1-12. Disponible sur https://journals.sagepub.com/doi/epub/10.1177/1756284820937115
  64. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Data base Syst Rev 2013; 12:1-276.
  65. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 ; 14 : 603-9.
  66. Haute autorité de santé. Traitement guidé de l’infection par Helicobacter pylori chez l’adulte [internet] [cité 26 avri 2023].Disponible surhttps://www.has-sante.fr/jcms/p_3282789/fr/choix-et-duree-de-l- antibiotherapie-traitement-guide-de-l-infection-par-helicobacter-pylori-chez-l-adulte
  67. Lamarque D, Burucoa C, Courillon-Mallet A, De Korwin J D, Delchier JC, Heluwaert F et al . Recommandations sur le traitement de l’infection à Helicobacter pylori chez l’adulte. Hépato Gastro et Oncologie digestive 2017 ; 24 : 157- 70.
  68. Shailja C. Shah, Prasad G. Iyer, Steven F Moss . AGA Clinical Practice Update on The Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021; 160: 1831-41.
  69. Nyssen OP, Perez-Aisa A, Castro-Fernandez M, et al. European registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021; 9: 38- 46.
  70. Howden CW, Graham DY. Recent developments pertaining to H. pylori infection. Am J Gastroenterol 2021 ;116 :1-3.
  71. Gisbert JP MA. Eradication of Helicobacter pylori infection with non-bismuth quadruple concomitant therapy. In: Rahman AU, Choudhary MI, eds. Frontiers in anti- infective drug discovery Bentham science publishers, 2020: 1–34.
  72. Haute autorité de santé. Choix et durée de l'antibiothérapie : Traitement probabiliste de l’infection par Helicobacter pylori chez l’adulte. [Internet] [cité 26 avri 2023]. Disponible sur https://www.has-sante.fr/jcms/p_3282793/fr/choix-et-duree-de-l-antibiotherapie-traitement-probabiliste-de-l-infection-par-helicobacter-pylori-chez-l-adulte
  73. Niv Y, Vaira D, Nyssen OP, et al. European registry on H. pylori management (HpEuReg): analysis of 1.782 empirical rescue therapies on third and subsequent lines. United European Gastroenterology Journal 2020; 8 :38.
  74. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP. Efficacy and Safety of Quinolone Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta- Analysis. Drugs 2017 ;77:765-76.
  75. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016 ; 151:51-69.
  76. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011 ;16 :420-6.
  77. Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta analysis. Helicobacter 2020;25: e12692.
  78. Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens. 2020;10:1-29.
  79. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert opinion on pharmacotherapy 2013;14:211-23.
  80. Amit KD, Perminder SP. Treatment of Helicobacter pylori infection in the presence of penicillinallergy. World J Gastroenterol 2021; 27: 7661-8.
  81. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet 2019; 393: 183-19
  82. Nyssen OP, Pérez- Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A et al. Helicobacter pylori first- line and rescue treatments in patients allergic to penicillin : Experience from the European Registry on H pylori management (Hp- EuReg). Helicobacter 2020; 25: e12686.
  83. Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L et al. Helicobacter pylori first line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015; 60: 458-64.
  84. Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton- pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018; 23:1-6.
  85. Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol 2019;19:1-9.
  86. Laisheng L, Yu H, Xiao L, Yingjie J, Lou Y, Hong L. Susceptibility- guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies. Helicobacter 2020; 25:1-8.
  87. Cynthia T. Nguyen , Kyle A. Davis, Sarah A. Nisly, Julius Li. Treatment of Helicobacter pylori in Special Patient Populations .Pharmacotherapy 2019;39 :1012-22.
  88. Haute autorité de santé .Traitement de l’infection par Helicobacter pylori chez l’adulte. [internet] [cité27avri 2023]. Disponiblesurhttps://www.hassante.fr/upload/docs/application/pdf/201706/dir83/helicobacter_fiche_pertinence_traitement.pdf
  89. Seiichi K, Toshiaki S, Shigeru T, Benjamin DG, Shinobu I Takashi I et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatrics International2020; 62:1315-31.
  90. Galicia Poblet G , Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B , Botija Arcos G , Cilleruelo Pascual ML et al .Management of Helicobacter pylori infection in the pediatric age. An Pediatr 2021;95 : e1-e9.
  91. Jones NL, Koletzko S, Goodman k, Bontems P, Cadranel S, Casswall T et al .Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016).J Pediatr Gastroenterol Nutr. 2017; 64:991-1003.
  92. Zhang M , Zhang C, Zhao J , Zhang H, Zhai O , Chen W et al. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy- associated side effects. Microb Pathog 2020 ;147:1-10.
  93. Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014;9:e111030.
  94. Lv Z, Wang BEN, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9:707-16.
  95. Zhou B-G, Chen L-X, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter 2019 ;24:e12651.
  96. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41:1237- 45.